This dataset contains counts of live births for California counties based on information entered on birth certificates. Final counts are derived from static data and include out of state births to California residents, whereas provisional counts are derived from incomplete and dynamic data. Provisional counts are based on the records available when the data was retrieved and may not represent all births that occurred during the time period.

The final data tables include both births that occurred in California regardless of the place of residence (by occurrence) and births to California residents (by residence), whereas the provisional data table only includes births that occurred in California regardless of the place of residence (by occurrence). The data are reported as totals, as well as stratified by parent giving birth's age, parent giving birth's race-ethnicity, and birth place type. See temporal coverage for more information on which strata are available for which years.

This is a publication on maternity activity in English NHS hospitals. This report examines data relating to delivery and birth episodes in 2023-24, and the booking appointments for these deliveries. This annual publication covers the financial year ending March 2024. Data is included from both the Hospital Episodes Statistics (HES) data warehouse and the Maternity Services Data Set (MSDS). HES contains records of all admissions, appointments and attendances for patients admitted to NHS hospitals in England. The HES data used in this publication are called 'delivery episodes'. The MSDS collects records of each stage of the maternity service care pathway in NHS-funded maternity services, and includes information not recorded in HES. The MSDS is a maturing, national-level dataset. In April 2019, the MSDS transitioned to a new version of the dataset. This version, MSDS v2.0, is an update that introduced a new structure and content - including clinical terminology, in order to meet current clinical practice and incorporate new requirements. It is designed to meet requirements that resulted from the National Maternity Review, which led to the publication of the Better Births report in February 2016. This is the fifth publication of data from MSDS v2.0 and data from 2019-20 onwards is not directly comparable to data from previous years. This publication shows the number of HES delivery episodes during the period, with a number of breakdowns including by method of onset of labour, delivery method and place of delivery. It also shows the number of MSDS deliveries recorded during the period, with a breakdown for the mother's smoking status at the booking appointment by age group. It also provides counts of live born term babies with breakdowns for the general condition of newborns (via Apgar scores), skin-to-skin contact and baby's first feed type - all immediately after birth. There is also data available in a separate file on breastfeeding at 6 to 8 weeks. For the first time information on 'Smoking at Time of Delivery' has been presented using annual data from the MSDS. This includes national data broken down by maternal age, ethnicity and deprivation. From 2025/2026, MSDS will become the official source of 'Smoking at Time of Delivery' information and will replace the historic 'Smoking at Time of Delivery' data which is to become retired. We are currently undergoing dual collection and reporting on a quarterly basis for 2024/25 to help users compare information from the two sources. We are working with data submitters to help reconcile any discrepancies at a local level before any close down activities begin. A link to the dual reporting in the SATOD publication series can be found in the links below. Information on how all measures are constructed can be found in the HES Metadata and MSDS Metadata files provided below. In this publication we have also included an interactive Power BI dashboard to enable users to explore key NHS Maternity Statistics measures. The purpose of this publication is to inform and support strategic and policy-led processes for the benefit of patient care. This report will also be of interest to researchers, journalists and members of the public interested in NHS hospital activity in England. Any feedback on this publication or dashboard can be provided to enquiries@nhsdigital.nhs.uk, under the subject “NHS Maternity Statistics”.

This statistical release presents the most recent monthly figures for NHS-funded maternity services in England, from data submitted to the Maternity Services Data Set (MSDS). This is the latest report from the newest version of the data set, MSDS.v.2, which has been in place since April 2019. The new data set was a significant change which added support for key policy initiatives such as continuity of carer, as well as increased flexibility through the introduction of new clinical coding. This was a major change, so data quality and coverage initially reduced from the levels seen in earlier publications. MSDS.v.2 data completeness improved over time, and we are looking at ways of supporting further improvements. This month four new measures have been included in this publication for the first time: reporting where safeguarding concerns have been raised during the pregnancy for the mother or the unborn child. This new data can be found in the Measures file available for download and further information on the new measures can be found in the accompanying Metadata file. Data derived from SNOMED codes is used in some measures such as those for smoking at booking and delivery, and birth weight, and others will follow in later publications. SNOMED data is also included in some of the published Clinical Quality Improvement Metrics (CQIMs), where rules have been applied to ensure measure rates are calculated only where data quality is high enough. System suppliers are at different stages of development and delivery to trusts. In some cases, this has limited the aspects of data that can be submitted in the MSDS. To help Trusts understand to what extent they met the Clinical Negligence Scheme for Trusts (CNST) Maternity Incentive Scheme (MIS) Data Quality Criteria for Safety Action 2, we have been producing a CNST Scorecard Dashboard showing trust performance against this criteria. This dashboard, now rebranded as the Maternity and Neonatal Programme MSDS Data Quality Priorities dashboard, can be accessed via the link below, includes data for July 2023 which is the assessment month for several of the criteria - and also the most recent data, for August and September 2023. These statistics are classified as experimental and should be used with caution. Experimental statistics are new official statistics undergoing evaluation. More information about experimental statistics can be found on the UK Statistics Authority website. The percentages presented in this report are based on rounded figures and therefore may not total to 100%.

The number of maternal deaths and maternal mortality rates for selected causes, 2000 to most recent year.

Mean age of mother at time of delivery, 1991 to most recent year.

Analysis of ‘🛟 Contraceptive Method Choice’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://www.kaggle.com/yamqwe/contraceptive-method-choicee on 13 February 2022.

--- Dataset description provided by original source is as follows ---

About this dataset

Dataset is a subset of the 1987 National Indonesia Contraceptive Prevalence Survey.# Source:
Origin:
This dataset is a subset of the 1987 National Indonesia Contraceptive Prevalence Survey
Creator:
Tjen-Sien Lim (limt '@' stat.wisc.edu)
Donor:
Tjen-Sien Lim (limt '@' stat.wisc.edu)

Data Set Information:

This dataset is a subset of the 1987 National Indonesia Contraceptive Prevalence Survey. The samples are married women who were either not pregnant or do not know if they were at the time of interview. The problem is to predict the current contraceptive method choice (no use, long-term methods, or short-term methods) of a woman based on her demographic and socio-economic characteristics.

Attribute Information:

1. Wife's age (numerical) 2. Wife's education (categorical) 1=low, 2, 3, 4=high 3. Husband's education (categorical) 1=low, 2, 3, 4=high 4. Number of children ever born (numerical) 5. Wife's religion (binary) 0=Non-Islam, 1=Islam 6. Wife's now working? (binary) 0=Yes, 1=No 7. Husband's occupation (categorical) 1, 2, 3, 4 8. Standard-of-living index (categorical) 1=low, 2, 3, 4=high 9. Media exposure (binary) 0=Good, 1=Not good 10. Contraceptive method used (class attribute) 1=No-use, 2=Long-term, 3=Short-term

Relevant Papers:

Lim, T.-S., Loh, W.-Y. & Shih, Y.-S. (1999). A Comparison of Prediction Accuracy, Complexity, and Training Time of Thirty-three Old and New Classification Algorithms. Machine Learning. ( or )

Papers That Cite This Data Set1:

Earl Harris Jr. Information Gain Versus Gain Ratio: A Study of Split Method Biases. The MITRE Corporation/Washington C. 2001.

• Soumya Ray and David Page. Generalized Skewing for Functions with Continuous and Nominal Attributes. Department of Computer Sciences and Department of Biostatistics and Medical Informatics, University of Wis.
• Jos'e L. Balc'azar. Rules with Bounded Negations and the Coverage Inference Scheme. Dept. LSI, UPC.

Citation Request:

Please refer to the Machine Learning Repository's citation policy.
[1] Papers were automatically harvested and associated with this data set, in collaborationwith Rexa.info

Source: http://archive.ics.uci.edu/ml/datasets/Contraceptive+Method+Choice

This dataset was created by UCI and contains around 1000 samples along with 1.1, 2.1, technical information and other features such as: - 2 - 3.1 - and more.

How to use this dataset

• Analyze 3 in relation to 1.2
• Study the influence of 24 on 1
• More datasets

Acknowledgements

If you use this dataset in your research, please credit UCI

Start A New Notebook!

--- Original source retains full ownership of the source dataset ---

This is a publication on maternity activity in English NHS hospitals. This report examines data relating to delivery and birth episodes in 2022-23, and the booking appointments for these deliveries. This annual publication covers the financial year ending March 2023. Data is included from both the Hospital Episodes Statistics (HES) data warehouse and the Maternity Services Data Set (MSDS). HES contains records of all admissions, appointments and attendances for patients admitted to NHS hospitals in England. The HES data used in this publication are called 'delivery episodes'. The MSDS collects records of each stage of the maternity service care pathway in NHS-funded maternity services, and includes information not recorded in HES. The MSDS is a maturing, national-level dataset. In April 2019 the MSDS transitioned to a new version of the dataset. This version, MSDS v2.0, is an update that introduced a new structure and content - including clinical terminology, in order to meet current clinical practice and incorporate new requirements. It is designed to meet requirements that resulted from the National Maternity Review, which led to the publication of the Better Births report in February 2016. This is the fourth publication of data from MSDS v2.0 and data from 2019-20 onwards is not directly comparable to data from previous years. This publication shows the number of HES delivery episodes during the period, with a number of breakdowns including by method of onset of labour, delivery method and place of delivery. It also shows the number of MSDS deliveries recorded during the period, with breakdowns including the baby's first feed type, birthweight, place of birth, and breastfeeding activity; and the mothers' ethnicity and age at booking. There is also data available in a separate file on breastfeeding at 6 to 8 weeks. The count of Total Babies includes both live and still births, and previous changes to how Total Babies and Total Deliveries were calculated means that comparisons between 2019-20 MSDS data and later years should be made with care. Information on how all measures are constructed can be found in the HES Metadata and MSDS Metadata files provided below. In this publication we have also included an interactive Power BI dashboard to enable users to explore key NHS Maternity Statistics measures. The purpose of this publication is to inform and support strategic and policy-led processes for the benefit of patient care. This report will also be of interest to researchers, journalists and members of the public interested in NHS hospital activity in England. Any feedback on this publication or dashboard can be provided to enquiries@nhsdigital.nhs.uk, under the subject “NHS Maternity Statistics”.

The second National Family Health Survey (NFHS-2), conducted in 1998-99, provides information on fertility, mortality, family planning, and important aspects of nutrition, health, and health care. The International Institute for Population Sciences (IIPS) coordinated the survey, which collected information from a nationally representative sample of more than 90,000 ever-married women age 15-49. The NFHS-2 sample covers 99 percent of India's population living in all 26 states. This report is based on the survey data for 25 of the 26 states, however, since data collection in Tripura was delayed due to local problems in the state. IIPS also coordinated the first National Family Health Survey (NFHS-1) in 1992-93. Most of the types of information collected in NFHS-2 were also collected in the earlier survey, making it possible to identify trends over the intervening period of six and one-half years. In addition, the NFHS-2 questionnaire covered a number of new or expanded topics with important policy implications, such as reproductive health, women's autonomy, domestic violence, women's nutrition, anaemia, and salt iodization. The NFHS-2 survey was carried out in two phases. Ten states were surveyed in the first phase which began in November 1998 and the remaining states (except Tripura) were surveyed in the second phase which began in March 1999. The field staff collected information from 91,196 households in these 25 states and interviewed 89,199 eligible women in these households. In addition, the survey collected information on 32,393 children born in the three years preceding the survey. One health investigator on each survey team measured the height and weight of eligible women and children and took blood samples to assess the prevalence of anaemia. SUMMARY OF FINDINGS POPULATION CHARACTERISTICS Three-quarters (73 percent) of the population lives in rural areas. The age distribution is typical of populations that have recently experienced a fertility decline, with relatively low proportions in the younger and older age groups. Thirty-six percent of the population is below age 15, and 5 percent is age 65 and above. The sex ratio is 957 females for every 1,000 males in rural areas but only 928 females for every 1,000 males in urban areas, suggesting that more men than women have migrated to urban areas. The survey provides a variety of demographic and socioeconomic background information. In the country as a whole, 82 percent of household heads are Hindu, 12 percent are Muslim, 3 percent are Christian, and 2 percent are Sikh. Muslims live disproportionately in urban areas, where they comprise 15 percent of household heads. Nineteen percent of household heads belong to scheduled castes, 9 percent belong to scheduled tribes, and 32 percent belong to other backward classes (OBCs). Two-fifths of household heads do not belong to any of these groups. Questions about housing conditions and the standard of living of households indicate some improvements since the time of NFHS-1. Sixty percent of households in India now have electricity and 39 percent have piped drinking water compared with 51 percent and 33 percent, respectively, at the time of NFHS-1. Sixty-four percent of households have no toilet facility compared with 70 percent at the time of NFHS-1. About three-fourths (75 percent) of males and half (51 percent) of females age six and above are literate, an increase of 6-8 percentage points from literacy rates at the time of NFHS-1. The percentage of illiterate males varies from 6-7 percent in Mizoram and Kerala to 37 percent in Bihar and the percentage of illiterate females varies from 11 percent in Mizoram and 15 percent in Kerala to 65 percent in Bihar. Seventy-nine percent of children age 6-14 are attending school, up from 68 percent in NFHS-1. The proportion of children attending school has increased for all ages, particularly for girls, but girls continue to lag behind boys in school attendance. Moreover, the disparity in school attendance by sex grows with increasing age of children. At age 6-10, 85 percent of boys attend school compared with 78 percent of girls. By age 15-17, 58 percent of boys attend school compared with 40 percent of girls. The percentage of girls 6-17 attending school varies from 51 percent in Bihar and 56 percent in Rajasthan to over 90 percent in Himachal Pradesh and Kerala. Women in India tend to marry at an early age. Thirty-four percent of women age 15-19 are already married including 4 percent who are married but gauna has yet to be performed. These proportions are even higher in the rural areas. Older women are more likely than younger women to have married at an early age: 39 percent of women currently age 45-49 married before age 15 compared with 14 percent of women currently age 15-19. Although this indicates that the proportion of women who marry young is declining rapidly, half the women even in the age group 20-24 have married before reaching the legal minimum age of 18 years. On average, women are five years younger than the men they marry. The median age at marriage varies from about 15 years in Madhya Pradesh, Bihar, Uttar Pradesh, Rajasthan, and Andhra Pradesh to 23 years in Goa. As part of an increasing emphasis on gender issues, NFHS-2 asked women about their participation in household decisionmaking. In India, 91 percent of women are involved in decision-making on at least one of four selected topics. A much lower proportion (52 percent), however, are involved in making decisions about their own health care. There are large variations among states in India with regard to women's involvement in household decisionmaking. More than three out of four women are involved in decisions about their own health care in Himachal Pradesh, Meghalaya, and Punjab compared with about two out of five or less in Madhya Pradesh, Orissa, and Rajasthan. Thirty-nine percent of women do work other than housework, and more than two-thirds of these women work for cash. Only 41 percent of women who earn cash can decide independently how to spend the money that they earn. Forty-three percent of working women report that their earnings constitute at least half of total family earnings, including 18 percent who report that the family is entirely dependent on their earnings. Women's work-participation rates vary from 9 percent in Punjab and 13 percent in Haryana to 60-70 percent in Manipur, Nagaland, and Arunachal Pradesh. FERTILITY AND FAMILY PLANNING Fertility continues to decline in India. At current fertility levels, women will have an average of 2.9 children each throughout their childbearing years. The total fertility rate (TFR) is down from 3.4 children per woman at the time of NFHS-1, but is still well above the replacement level of just over two children per woman. There are large variations in fertility among the states in India. Goa and Kerala have attained below replacement level fertility and Karnataka, Himachal Pradesh, Tamil Nadu, and Punjab are at or close to replacement level fertility. By contrast, fertility is 3.3 or more children per woman in Meghalaya, Uttar Pradesh, Rajasthan, Nagaland, Bihar, and Madhya Pradesh. More than one-third to less than half of all births in these latter states are fourth or higher-order births compared with 7-9 percent of births in Kerala, Goa, and Tamil Nadu. Efforts to encourage the trend towards lower fertility might usefully focus on groups within the population that have higher fertility than average. In India, rural women and women from scheduled tribes and scheduled castes have somewhat higher fertility than other women, but fertility is particularly high for illiterate women, poor women, and Muslim women. Another striking feature is the high level of childbearing among young women. More than half of women age 20-49 had their first birth before reaching age 20, and women age 15-19 account for almost one-fifth of total fertility. Studies in India and elsewhere have shown that health and mortality risks increase when women give birth at such young ages?both for the women themselves and for their children. Family planning programmes focusing on women in this age group could make a significant impact on maternal and child health and help to reduce fertility. INFANT AND CHILD MORTALITY NFHS-2 provides estimates of infant and child mortality and examines factors associated with the survival of young children. During the five years preceding the survey, the infant mortality rate was 68 deaths at age 0-11 months per 1,000 live births, substantially lower than 79 per 1,000 in the five years preceding the NFHS-1 survey. The child mortality rate, 29 deaths at age 1-4 years per 1,000 children reaching age one, also declined from the corresponding rate of 33 per 1,000 in NFHS-1. Ninety-five children out of 1,000 born do not live to age five years. Expressed differently, 1 in 15 children die in the first year of life, and 1 in 11 die before reaching age five. Child-survival programmes might usefully focus on specific groups of children with particularly high infant and child mortality rates, such as children who live in rural areas, children whose mothers are illiterate, children belonging to scheduled castes or scheduled tribes, and children from poor households. Infant mortality rates are more than two and one-half times as high for women who did not receive any of the recommended types of maternity related medical care than for mothers who did receive all recommended types of care. HEALTH, HEALTH CARE, AND NUTRITION Promotion of maternal and child health has been one of the most important components of the Family Welfare Programme of the Government of India. One goal is for each pregnant woman to receive at least three antenatal check-ups plus two tetanus toxoid injections and a full course of iron and folic acid supplementation. In India, mothers of 65 percent of the children born in the three years preceding NFHS-2 received at least one antenatal

Number and percentage of live births, by month of birth, 1991 to most recent year.

Between April and June 2011, 486 facilities in Malawi were providing PMTCT at ANC and/or maternity. 7,524 (85%) of 8,525 women attending ANC who were known to be HIV positive received ARVs. This represents 40% PMTCT coverage among the estimated 18,210 HIV positive pregnant women in Malawi during this quarter. 5,804 (94%) _of 6,172 infants born to known HIV infected mothers at maternity received ARV prophylaxis. This represents _32% PMTCT coverage among the estimated 18,210 HIV exposed infants born in Malawi during this quarter. Based on the expected number of women attending ANC each quarter, this report is estimated to be 80% complete. Several sites had not submitted their reports despite all attempts to chase up outstanding data in the passive reporting system that is used up to now. It is hoped that integrated PMTCT/ART supervision covering all PMTCT sites will improve this situation from next quarter.

This data set includes demographic, clinical data, result of Giemsa staining and molecular test for urine and high vaginal swab of infertile Sudanese women screened for Chlamydia trachomatis.participants in data were classified into two groups as follow: primary infertile women those failed to get pregnant (and no abortion exposure) for at least one year after marriage, and the secondary infertile women those exposed to abortion/s and/or successful pregnancy/ies before but now they fail to get pregnant

whatsapp +971521553488 Abortion Pills In Sharjah dubai♻️)abortion pills in bahrain qatar(+971521553488 misoprostol in dubai doha ,cytotec pills/tablets in dubai ajman,abortion pills in abu dhabi,kuwaitcity .al ain abortion pills in muscat oman Abortion Pills in Dubai/oman/misoprostol in Abudhabi/Fujairah +971521553488 )-mifepristone & misoprostol in Dubai/Abu Dhabi/cytotec in kuwaitcity Sharjah-cytotec in Dubai/Ajman/RAK-Abortion pills for sale in DUBAI CONTACT DR.Leen Whatsapp ++971521553488Where We have Abortion Pills in qatar/ Cytotec Tablets /mifegest kit Available in Dubai, Sharjah, Abudhabi, Ajman, Alain, Fujairah, Ras Al Khaimah, Umm Al Quwain, UAE, buy cytotec in Dubai +971521553488Where “”Abortion Pills near me DUBAI | ABU DHABI|UAE. Price of Misoprostol, Cytotec” +971521553488Where “BUY ABORTION PILLS MIFEGEST KIT, MISOPROTONE, CYTOTEC PILLS IN DUBAI, ABU DHABI,UAE” Contact me now via whatsapp…… abortion Pills Cytotec also available Oman Qatar Doha Saudi Arabia Bahrain Above all, Cytotec Abortion Pills are Available In Dubai / UAE, you will be very happy to do abortion in dubai we are providing cytotec 200mg abortion pill in Dubai+971521553488, UAE. Medication abortion offers an alternative to Surgical Abortion for women in the early weeks of pregnancy. We only offer abortion pills from 1 week-6 Months. We then advice you to use surgery if its beyond 6 months. Our Abu Dhabi, Ajman, Al Ain, Dubai, Fujairah, Ras Al Khaimah (RAK), Sharjah, Umm Al Quwain (UAQ) United Arab Emirates Abortion Clinic provides the safest and most advanced techniques for providing non-surgical, medical and surgical abortion methods for early through late second trimester, including the Abortion By Pill Procedure (RU 486, Mifeprex, Mifepristone, early options French Abortion Pill), Tamoxifen, Methotrexate and Cytotec (Misoprostol). The Abu Dhabi, United Arab Emirates Abortion Clinic performs Same Day Abortion Procedure using medications that are taken on the first day of the office visit and will cause the abortion to occur generally within 4 to 6 hours (as early as 30 minutes) for patients who are 3 to 12 weeks pregnant. When Mifepristone and Misoprostol are used, 50% of patients complete in 4 to 6 hours; 75% to 80% in 12 hours; and 90% in 24 hours. We use a regimen that allows for completion without the need for surgery 99% of the time. All advanced second trimester and late term pregnancies at our Tampa clinic (17 to 24 weeks or greater) can be completed within 24 hours or less 99% of the time without the need surgery. The procedure is completed with minimal to no complications. Our Women’s Health Center located in Abu Dhabi, United Arab Emirates,+971521553488Where uses the latest medications for medical abortions (RU486, Mifeprex, Mifegyne, Mifepristone, early options French abortion pill), Methotrexate and Cytotec (Misoprostol). The safety standards of our Abu Dhabi, United Arab Emirates Abortion Doctors remain unparalleled. They consistently maintain the lowest complication rates throughout the nation. Our Physicians and staff are always available to answer questions and care for women in one of the most difficult times in their life. The decision to have an abortion at the Abortion Clinic in Abu Dhabi, United Arab Emirates, involves moral, ethical, religious, family, financial, health and age considerations. Buy abortion pills in Dubai, Buy abortion pills in Oman, Buy abortion pills in Abu Dhabi, Buy abortion pills in Sharjah Fujairah, Buy abortion pills in Ras Al Khaimah (RAK), Buy abortion pills in Ajman, Buy abortion pills in Al Ain, Buy abortion pills in Umm Al Quwain (UAQ), Buy abortion pills in Kuwait, Abortion Pills Available In Dubai, Abortion Pills Available In UAE, Abortion Pills Available In Abu Dhabi, Abortion Pills Available In Sharjah, Abortion Pills Available In Fujairah, Abortion Pills Available In Alain, Abortion Pills Available In Qatar, Cytotec Available In Dubai Cytotec in Dubai, abortion pills in Dubai for sale+971521553488Where Cytotec Pills Dubai, Abortion Cytotec Pills In Dubai UAE, Whatsapp +971521553488Where Question Tags: +971521553488Where “Legit & Safe ABORTION PILLS, ABU DHABI Sharjah Alain RAK city Satwa Jumeirah Al barsha, CYTOTEC, MIFEGEST KIT IN DUBAI, Misoprostol, UAE” Contact me now via whatsapp………….+971521553488Where

Note: An error was identified in Table 6 of these National tables. As part of the process to thoroughly quality assure the rest of the publication, two further errors were found. These affect Table 9 in the National tables, Table 6 in the SHA tables and Table 3 in the PCT tables. None of the errors affect any key national figures. These errors have now been rectified. In Table 6 of the National tables the number of successful quitters per 100,000 population for England has been amended. In Table 9 of the National tables and Table 6 of the SHA tables, the data submitted by one PCT for NS-SEC (socio-economic classification) was incomplete. The numbers and corresponding percentages in the 'unable to code' category have been amended. A percentage in Table 3 of the PCT tables was incorrect. Other columns in this table were unaffected. Here a mistake was made when suppressing unsafe cells. Please see tables for details of amendments. Summary: This quarterly report presents provisional results from the monitoring of the NHS Stop Smoking Services (NHS SSS) in England during the period April to December 2008. This report includes information on the number of people setting a quit date and the number who successfully quit at the 4 week follow-up. It also presents more in depth analyses of the key measures of the service including pregnant women; breakdowns by ethnic groups and type of pharmacotherapy received; regional analyses at Strategic Health Authority (SHA) and Primary Care Trust (PCT) levels. This release also sees the inclusion of more detailed PCT results for the first time. In 2008/09 there have been new data items added to the collection. This includes data for the number of people setting a quit date and the number who successfully quit at the 4 week follow-up categorised by socio economic classification, eligibility to receive free prescriptions, intervention setting and intervention type. This bulletin reports on these newly collected data items. However there are weaknesses with this newly collected data as is common with new data collections within their first year, but rather than withhold this already useful dataset we are releasing it labelled 'experimental statistics' and are seeking input from users to help us improve it.

(+966505195917)☎️

Where to buy Abortion (cytotec)pills in kuwait(+966505195917)☎️

Abortion pills in al Farwaniyah, Kuwait |abortion pills in Al Asimah, Kuwait |(+966505195917)abortion pills in Al Ahmadi, Kuwait |abortion pills in Al Jahra, Kuwait |(+966505195917)

Abortion pills in Hawalli, Kuwait |(+966505195917)☎️

Abortion(cytotec) pills in Kuwait City, Kuwait |(+966505195917)☎️

Abortion pills in Mubarak Al-Kabeer, Kuwait(+966505195917) | ☎️abortion (cytotec)pills in Salmiya Kuwait (+966505195917)☎️

Abortion (cytotec)pills in Oman:-Muscat,Adam.

As Sib.(+966505195917)☎️

Al Ashkharah.

Al Buraimi.

Al Hamra.(+966505195917)☎️

Al Jazer.

Al Madina A'Zarqa (formerly known as Blue City)(+966505195917)☎️

Al Suwaiq.Qatar,Dubai UAE(+966505195917)☎️

Abortion(cytotec) pills in Saudi Arabia ★+966505195917★☎️

Abortion pills in Riyadh

Abortion pills in Jeddah

Abortion pills in dammam

Abortion pills in taif

Abortion pills in tabuk

Abortion pills in Makkah,madina

Abortion (cytotec)pills in Qatar doha ★+966505195917☎️

What is Abortion ?

★+966505195917☎️

An abortion is medically referred to as a therapeutic abortion when it is performed to save the life of the pregnant woman; to prevent harm to the woman's physical or mental health; to terminate a pregnancy where indications are that the child will have a significantly increased chance of mortality or morbidity; or to …An induced abortion is different from a spontaneous abortion. That is the loss of a pregnancy before the 20th week of pregnancy. It is more commonly known as a miscarriage.

★+966505195917☎️

★+966505195917☎️

Kind of abortion :

★+966505195917☎️

There are 2 types of abortion:

1.Medical, which uses (cytotec)medication.

2.Surgical, which involves a small operation.

+966505195917☎️

+966505195917☎️

Medical abortion (cytotec)procedure:

+966505195917☎️

Mifepristone 200mg

Misoprostal 200mg

(Cytotec ) Pfizer is an American brand used to terminate pregnancy.

+966505195917☎️

How mifepristone work?

+966505195917☎️

Mifepristone is a medication used in medical abortion (abortion pill) procedures. It works by blocking the hormone progesterone, which is necessary to maintain the lining of the uterus where a fertilized egg would normally implant and develop. Without progesterone, the lining breaks down, making it difficult for the pregnancy to continue. Mifepristone is often used in combination with another medication called misoprostol to induce contractions and complete the abortion process.

☎️+966505195917☎️

How misoprostal (cytotec)work?

☎️+966505195917☎️

Misoprostol is a medication that is used in combination with mifepristone for medical abortions. It works primarily by causing contractions of the uterus, which helps expel the contents of the uterus, including the embryo or fetus.

☎️+966505195917☎️

Here's how misoprostol (cytotec)works in the context of abortion:

+966505195917☎️

Softening of the cervix: Misoprostol helps soften the cervix (the lower part of the uterus), which makes it easier for the uterus to expel its contents.

+966505195917☎️

Uterine contractions: It stimulates strong uterine contractions, similar to those that occur during labor, to expel the pregnancy tissue.

☎️+966505195917★᭄

Completing the abortion process: When used after mifepristone, misoprostol ensures the expulsion of the remaining contents of the uterus, completing the abortion process.

☎️+966505195917★

Medical abortions using mifepristone and misoprostol are generally safe and effective when used according to medical guidelines and under medical supervision.

★+966505195917★☎️

Medical abortion(cytotec) guidline :

★☎️+966505195917★

For medical abortion at < 12 weeks:

1.Recommend the use of 200 mg mifepristone administered orally, followed 1–2 days later by 800 μg misoprostol administered vaginally, sublingually or buccally. ...

2.When using misoprostol alone: Recommend the use of 800 μg misoprostol administered buccally, sublingually or vaginally.

Surgical Abortion guidline:

★☎️+966505195917

Surgical abortion, also known as suction aspiration abortion, can be performed in a one-day procedure if less than 14 weeks have passed since the first day of your last menstrual period. The procedure is done in the doctor's office with local anesthesia and oral pain-relieving medications.

★+966505195917★☎️

The reasons for having an (cytotec)abortion are:

★+966505195917★

Don't want to have children because you are worried it will disrupt your career.

Don't want to have children without a father.

Pregnant due to infidelity.

Pregnant out of wedlock.

The child's condition is still small.

Pregnancy conditions that are dangerous for the mother.

Abortion performed against a defective fetus.

Abortion done for other reasons.

★+966505195917★☎️

Side Effects of the Abortion (cytotec)Drug Cytotec Misoprostol

★+966505195917★☎️

Nausea or stomach cramps may occur. If any of these effects persist or worsen, notify us immediately.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this drug do not have serious side effects.

Diarrhea is common with the drug misoprostol and usually occurs about two weeks after you start taking it, and lasts for about a week. Make sure to maintain fluid and mineral/electrolyte intake to prevent dehydration. Persistent diarrhea can sometimes cause major losses of body fluids and minerals. Tell your doctor immediately if you experience any of these serious signs of dehydration and mineral imbalance, severe dizziness.

★☎️+966505195917★

ADVANTAGES OF CYTOTEC (medical) TERMINATION DRUG:

★+966505195917★☎️

Abort the pregnancy quickly and completely.

The results after taking cytotec and gastrul drugs are like a natural miscarriage.

It doesn't cost much.

Can be used in early pregnancy.

No need for surgical intervention.

6.Success rate reaches 99%.

★+966505195917★

Abortion is carried out by pregnant women, both married and unmarried, for various reasons, but the main reasons are non-medical reasons (including self-abortion/intentional/artificial)

★+966505195917★

Usage of (cytotec)abortion pills:

(As prescribed by the physician)

★☎️+966505195917★☎️

Appeal: For those of you who really want to abort a pregnancy, now there are lots of patients who come and complain about the circulation of fake abortion drugs being sold. We advise you not to be tempted by cheap abortion drug prices.

★☎️+966505195917★☎️